JP2021524451A5 - - Google Patents
Info
- Publication number
- JP2021524451A5 JP2021524451A5 JP2020564553A JP2020564553A JP2021524451A5 JP 2021524451 A5 JP2021524451 A5 JP 2021524451A5 JP 2020564553 A JP2020564553 A JP 2020564553A JP 2020564553 A JP2020564553 A JP 2020564553A JP 2021524451 A5 JP2021524451 A5 JP 2021524451A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- polypeptide chain
- seq
- acid sequence
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862673462P | 2018-05-18 | 2018-05-18 | |
| US62/673,462 | 2018-05-18 | ||
| PCT/US2019/032030 WO2019222104A1 (en) | 2018-05-18 | 2019-05-13 | Optimized gp41-binding molecules and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021524451A JP2021524451A (ja) | 2021-09-13 |
| JP2021524451A5 true JP2021524451A5 (enExample) | 2022-05-16 |
Family
ID=68540936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564553A Pending JP2021524451A (ja) | 2018-05-18 | 2019-05-13 | 最適化済みｇｐ４１結合分子及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210246194A1 (enExample) |
| EP (1) | EP3794027A4 (enExample) |
| JP (1) | JP2021524451A (enExample) |
| CN (1) | CN112533945A (enExample) |
| AU (1) | AU2019269383A1 (enExample) |
| BR (1) | BR112020023432A2 (enExample) |
| CA (1) | CA3100398A1 (enExample) |
| IL (1) | IL278832A (enExample) |
| MX (1) | MX2020012309A (enExample) |
| SG (1) | SG11202011355QA (enExample) |
| WO (1) | WO2019222104A1 (enExample) |
| ZA (1) | ZA202007056B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10647768B2 (en) * | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
| EA201790719A1 (ru) * | 2014-09-26 | 2017-07-31 | Макродженикс, Инк. | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения |
| US11795226B2 (en) * | 2017-12-12 | 2023-10-24 | Macrogenics, Inc. | Bispecific CD16-binding molecules and their use in the treatment of disease |
| CN111647078B (zh) * | 2020-06-22 | 2022-04-26 | 中国医学科学院医学生物学研究所 | 一种抗hiv的单克隆抗体及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009036379A2 (en) * | 2007-09-14 | 2009-03-19 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| CA2906566C (en) * | 2013-03-14 | 2024-09-10 | Macrogenics, Inc. | Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor |
| US9988438B2 (en) * | 2013-07-25 | 2018-06-05 | Board of Supervisor of Louisiana State University and Agricultural and Mechanical College | Anti-HIV dual specificity antibodies and methods of HIV treatment |
| UA116479C2 (uk) * | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
| US10647768B2 (en) * | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
| WO2016054101A1 (en) * | 2014-09-29 | 2016-04-07 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
| AU2016249404B2 (en) * | 2015-04-17 | 2021-01-21 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| JP7725185B2 (ja) * | 2015-10-06 | 2025-08-19 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体及びその使用方法 |
| MX2018014950A (es) * | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
-
2019
- 2019-05-13 EP EP19802868.0A patent/EP3794027A4/en active Pending
- 2019-05-13 CN CN201980048041.9A patent/CN112533945A/zh active Pending
- 2019-05-13 SG SG11202011355QA patent/SG11202011355QA/en unknown
- 2019-05-13 MX MX2020012309A patent/MX2020012309A/es unknown
- 2019-05-13 AU AU2019269383A patent/AU2019269383A1/en not_active Abandoned
- 2019-05-13 JP JP2020564553A patent/JP2021524451A/ja active Pending
- 2019-05-13 CA CA3100398A patent/CA3100398A1/en active Pending
- 2019-05-13 WO PCT/US2019/032030 patent/WO2019222104A1/en not_active Ceased
- 2019-05-13 BR BR112020023432-0A patent/BR112020023432A2/pt not_active IP Right Cessation
- 2019-05-13 US US17/055,805 patent/US20210246194A1/en active Pending
-
2020
- 2020-11-12 ZA ZA2020/07056A patent/ZA202007056B/en unknown
- 2020-11-18 IL IL278832A patent/IL278832A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Bispecific antibodies: from research to clinical application | |
| Hosseini et al. | Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials | |
| Riethmüller | Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on | |
| JP2020055858A5 (enExample) | ||
| JP2023106433A5 (enExample) | ||
| JP2022510218A5 (enExample) | ||
| JP2021098732A5 (enExample) | ||
| JP2020529410A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021524267A5 (enExample) | ||
| JP2021522162A5 (enExample) | ||
| IL271325B2 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| JP2019536430A5 (enExample) | ||
| WO2019005641A1 (en) | GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF | |
| JP2016536322A5 (enExample) | ||
| JP2018533371A5 (enExample) | ||
| JP2022551081A5 (enExample) | ||
| RU2016114504A (ru) | Би- или полиспецифические полипептиды, связывающие поверхностные антигены иммунных эффекторных клеток и антигены hbv для лечения инфекций bv и ассоциированных с ними состояний | |
| RU2007145419A (ru) | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами | |
| JP2022515152A5 (enExample) | ||
| JP2022505445A5 (enExample) | ||
| JP2024507540A5 (enExample) | ||
| JP2023551535A5 (enExample) | ||
| JP2023506834A5 (enExample) | ||
| JP2021526377A5 (enExample) |